Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva is poised for growth with a diverse portfolio of royalty healthcare assets, a strong financial performance, and a focus on developing innovative treatments for antibiotic-resistant infections and depression. Their products, including Xacduro and Giapreza, have shown promising clinical results and are filling crucial gaps in the healthcare market. Additionally, Innoviva is adapting to the changing landscape of healthcare with the implementation of telemedicine and at-home test kits.

Bears say

Innoviva is facing multiple challenges in its royalty portfolio, with potential competition from new drugs such as Blujepa and Nuzolvence for ESBL and carbapenem-resistant infections. Additionally, while their acquisitions of Lyndra and Syndeio Biosciences offer potential for oral dosing and treatments for synaptic diseases, the success of these drugs is uncertain and may not provide significant financial gains. The company's reliance on one major royalty contributor, GlaxoSmithKline, poses a significant risk to their income if there were to be any issues with the performance of GlaxoSmithKline's products in the market.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.